These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 1705407)
1. Pharmacologic manipulation of fetal hemoglobin. Update on clinical trials with hydroxyurea. Dover GJ Ann N Y Acad Sci; 1990; 612():184-90. PubMed ID: 1705407 [No Abstract] [Full Text] [Related]
2. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Pearson HA Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181 [No Abstract] [Full Text] [Related]
3. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy to increase fetal hemoglobin in patients with sickle cell anemia. Platt OS Am J Pediatr Hematol Oncol; 1985; 7(3):258-60. PubMed ID: 2416231 [TBL] [Abstract][Full Text] [Related]
5. Progress toward increasing fetal hemoglobin production in man: experience with 5-azacytidine and hydroxyurea. Dover GJ; Charache S; Nora R; Boyer SH Ann N Y Acad Sci; 1985; 445():218-24. PubMed ID: 2409873 [No Abstract] [Full Text] [Related]
6. Hydroxyurea: specific therapy for sickle cell anemia? Kaufman RE Blood; 1992 May; 79(10):2503-6. PubMed ID: 1375102 [No Abstract] [Full Text] [Related]
7. Hydroxyurea therapy in thalassemia. Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia? Fathallah H; Sutton M; Atweh GF Ann N Y Acad Sci; 2005; 1054():228-37. PubMed ID: 16339670 [TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea and sickle cell disease: a chance for every patient. Weiner DL; Brugnara C JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739 [No Abstract] [Full Text] [Related]
10. Long-term use of hydroxyurea for sickle cell anemia. Hagar W JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424 [No Abstract] [Full Text] [Related]
11. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325 [TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea, sickle cell disease and renal transplantation. Allen A; Scoble J; Snowden S; Hambley H; Bellingham A Nephron; 1997; 75(1):106-7. PubMed ID: 9031282 [No Abstract] [Full Text] [Related]
13. Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease. Dover GJ; Charache S Semin Oncol; 1992 Jun; 19(3 Suppl 9):61-6. PubMed ID: 1379374 [TBL] [Abstract][Full Text] [Related]
14. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and hemoglobin F synthesis in sickle cell disease. Dover GJ; Charache S Ann N Y Acad Sci; 1989; 565():222-7. PubMed ID: 2476061 [No Abstract] [Full Text] [Related]